bisulfite pyrosequencing  (Pyrosequencing Inc)

Journal: Frontiers in Genetics

Article Title: Promoter hypomethylation of CDH7 : a novel epigenetic marker associated with cerebral small vessel disease

doi: 10.3389/fgene.2026.1780415

Figure Lengend Snippet: Genomic structure of promoter CpG islands and regions analyzed by bisulfite pyrosequencing for CDH7 and ZNF234 identified via the Illumina EPIC array. Promoter regions of CDH7 (chr18:65,749,012-65,751,346) and ZNF234 (chr19:44,139,554-44,141,888) were amplified and included exon 1 indicated by open boxes. Black boxes represent regions targeted in CDH7 (177 bp) and ZNF234 (223 bp) for bisulfite pyrosequencing, and the small open segment within each black box indicates the sequencing primer binding site for CDH7 and ZNF234 . Genomic coordinates are based on the GRCh38/hg38 reference genome.

Article Snippet: Evaluation of promoter methylation status revealed that CDH7 pyrosequencing demonstrated >20% methylation (no-SVD: 23.1%; all-SVD: 25.8%), whereas ZNF234 pyrosequencing showed ≤5% methylation (no-SVD: 2.8%; all-SVD: 5.8%) in the 16 no-SVD and 16 all-SVD patients selected for the MethylationEPIC array ( ).

Techniques: Amplification, Sequencing, Binding Assay

Journal: Frontiers in Genetics

Article Title: Promoter hypomethylation of CDH7 : a novel epigenetic marker associated with cerebral small vessel disease

doi: 10.3389/fgene.2026.1780415

Figure Lengend Snippet: Box plots showing the promoter methylation status of CDH7 in monocytes, T cells, B cells, and buffy coats from the peripheral blood of 89 patients with ischemic stroke. Within each box, horizontal white lines indicate median values; boxes represent the interquartile range (25th–75th percentiles); whiskers denote adjacent values; and dots represent outliers. * P < 0.01 by analysis of variance (ANOVA) comparing methylation levels among monocytes, T cells, and B cells.

Article Snippet: Evaluation of promoter methylation status revealed that CDH7 pyrosequencing demonstrated >20% methylation (no-SVD: 23.1%; all-SVD: 25.8%), whereas ZNF234 pyrosequencing showed ≤5% methylation (no-SVD: 2.8%; all-SVD: 5.8%) in the 16 no-SVD and 16 all-SVD patients selected for the MethylationEPIC array ( ).

Techniques: Methylation

Journal: Frontiers in Genetics

Article Title: Promoter hypomethylation of CDH7 : a novel epigenetic marker associated with cerebral small vessel disease

doi: 10.3389/fgene.2026.1780415

Figure Lengend Snippet: Relationship between CDH7 promoter methylation and gene expression across eight human cancer cell lines exhibiting different levels of promoter methylation. The ΔCt value represents the difference in threshold cycles between CDH7 and the internal control beta actin ( ACTB) , calculated by subtracting C T of ACTB from C T of CDH7 .

Article Snippet: Evaluation of promoter methylation status revealed that CDH7 pyrosequencing demonstrated >20% methylation (no-SVD: 23.1%; all-SVD: 25.8%), whereas ZNF234 pyrosequencing showed ≤5% methylation (no-SVD: 2.8%; all-SVD: 5.8%) in the 16 no-SVD and 16 all-SVD patients selected for the MethylationEPIC array ( ).

Techniques: Methylation, Gene Expression, Control

Journal: Frontiers in Genetics

Article Title: Promoter hypomethylation of CDH7 : a novel epigenetic marker associated with cerebral small vessel disease

doi: 10.3389/fgene.2026.1780415

Figure Lengend Snippet: Feature importance (left panel) and impact on model output (right panel) of individual variables derived from aggregated Shapley Additive exPlanations (SHAP) analysis. CDH7, cadherin-7 promoter methylation; DM, previous history of diabetes; GPT, glutamic pyruvic transaminase; Hb, hemoglobin; HbA1c, hemoglobin A1c; Hcy, homocysteine; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; HT, previous history of hypertension; LDL, low-density lipoprotein; Plt, platelet; TG, triglyceride; T-chol., total cholesterol; WBC, white blood cell.

Article Snippet: Evaluation of promoter methylation status revealed that CDH7 pyrosequencing demonstrated >20% methylation (no-SVD: 23.1%; all-SVD: 25.8%), whereas ZNF234 pyrosequencing showed ≤5% methylation (no-SVD: 2.8%; all-SVD: 5.8%) in the 16 no-SVD and 16 all-SVD patients selected for the MethylationEPIC array ( ).

Techniques: Derivative Assay, Methylation